Loading stock data…
LUCD
$0.99+0.03 (+3.28%)
After Hours$0.99+0.00 (+0.06%)· Last close Jun 9
Lucid Diagnostics Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lucid Diagnostics Inc. in the Healthcare sector is trading at $0.99. Wall Street consensus targets $3.95 (5 analysts), implying a +299.2% move over the next 12 months. The stock is currently near its 52-week low of $0.90, remaining 14.7% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +299.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$0.99
Potential Downside
0%
Whystock Fair Value$0.99
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, prima...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1125.28%
Volume
Today's trading volume
1.08M
Recent News
Why Lucid Diagnostics Inc. (LUCD) Faced a Price Target Reduction After Q1 Results
We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. Lucid Diagnostics Inc. (NASDAQ:LUCD) is also on this list of popular penny stocks. TheFly reported on May 15 that Maxim Group reduced its price target on LUCD from $3 to $2 while maintaining a Buy rating following a […]
Lucid Diagnostics Inc (LUCD) Q1 2026 Earnings Call Highlights: Exceeding Test Targets and ...
Despite revenue challenges, Lucid Diagnostics Inc (LUCD) makes strides in federal contracts and commercial payer engagements.
Lucid Diagnostics Inc. Q1 2026 Earnings Call Summary
Moby summary of Lucid Diagnostics Inc.'s Q1 2026 earnings call
LUCD Q1 2026 Earnings Transcript
Matthew Riley: Thank you, operator, and good morning, everyone. Thank you for participating in today's business update call. Joining me today on the call are Dr. Lishan Aklog, Chairman and Chief Executive Officer of Lucid Diagnostics; along with Dennis McGrath, Chief Financial Officer of Lucid Diagnostics.
Lucid Diagnostics Q1 Earnings Call Highlights
Lucid Diagnostics (NASDAQ:LUCD) reported first-quarter 2026 EsoGuard test volume above its pre-Medicare target range, while management said it continues to await a Medicare local coverage determination and is expanding efforts with the Department of Veterans Affairs, commercial payers and health sys